Riferimento farmaci
Elacestrant
Elacestrant is a medicine in the class oncology. It is used for breast cancer.
- Classe del farmaco: Oncology
- Indicato per: breast cancer
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Forme farmaceutiche comuni
- compressa
- Interazioni note
- 50 (Maggiore: 20 · Moderata: 23 · Minore: 7)
- Nomi commerciali
- 2
- Paesi e mercati
- 2
Per cosa si usa
Come agisce
Elacestrant is an estrogen receptor antagonist that binds to ERα and inhibits estradiol-mediated proliferation of ER+ HER2- breast cancer cells, with degradation of ERα protein via the proteasomal pathway.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer: 345 mg orally with food once daily until disease progression or unacceptable toxicity
Gravidanza e allattamento
- Gravidanza
- Unsafe Can cause fetal harm: in rats it caused embryo-fetal death and limb and skull malformations below human exposure; no human data. Verify pregnancy status first. Women, and men with female partners, should use effective contraception during treatment and for 1 week after.
- Allattamento
- Unsafe No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 week after the last dose.
Effetti indesiderati segnalati
- Musculoskeletal pain
- Nausea
- Increased cholesterol
- Increased AST
- Increased triglycerides
- Fatigue
Chi deve prestare attenzione
- Dyslipidemia: hypercholesterolemia and hypertriglyceridemia may occur; monitor lipid profile before starting and periodically.
- Embryo-fetal toxicity: can cause fetal harm; advise effective contraception during treatment and for 1 week after the last dose.
- May impair fertility in females and males of reproductive potential.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (50)
- Amobarbital + Elacestrant Major
- Apalutamide + Elacestrant Major
- Aprepitant + Elacestrant Major
- Armodafinil + Elacestrant Major
- Carbamazepine + Elacestrant Major
- Clarithromycin + Elacestrant Major
- Efavirenz + Elacestrant Major
- Elacestrant + Enzalutamide Major
- Elacestrant + Erythromycin Major
- Elacestrant + Eslicarbazepine Major
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Elacestrant: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Elacestrant used for?
Elacestrant is a medicine in the class oncology. It is used for Breast cancer.
What side effects have been reported with Elacestrant?
Musculoskeletal pain, Nausea, Increased cholesterol, Increased AST, Increased triglycerides, Fatigue.
Can Elacestrant be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats it caused embryo-fetal death and limb and skull malformations below human exposure; no human data. Verify pregnancy status first. Women, and men with female partners, should use effective contraception during treatment and for 1 week after. Breastfeeding: Unsafe. No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 week after the last dose.
What does Elacestrant interact with?
MediHelp lists 50 known interactions for Elacestrant. Major: 20 · Moderate: 23 · Minor: 7. The most serious include Amobarbital, Apalutamide, Aprepitant.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
